COMP <GO>
STAA vs MRK // GROSS PROFIT MARGIN
STAAR Surgical Company (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: STAA 3
— MRK 8
▲ GROSS PROFIT MARGIN LEADER: STAA
LAST: $25.24 (+2.56%) • MKT CAP: $1.27B
gross-margins
76.20%
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STAA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | STAA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 76.20% | 74.80% | +1.40 | STAA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.16% | 3.42% | -6.58 | MRK | /fcf-yield <GO> |
| Operating Margin | -38.30% | 34.30% | -72.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | -33.60% | 28.10% | -61.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -23.70% | 1.30% | -25.00 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.11 | 5.19 | +1.92 | STAA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.8 | 51.7 | +10.05 | STAA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.27B | $361.02B | -$359.76B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | STAA REV | MRK REV | STAA GROSS % | MRK GROSS % | STAA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $239.4M | $65.01B | 76.2% | 74.8% | -$40.0M | $12.36B |
| FY 2024 | $313.9M | $64.17B | 76.3% | 76.3% | -$7.7M | $18.10B |
| FY 2023 | $322.4M | $60.12B | — | — | $14.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STAA // BETA —
MRK // BETA 0.92